DYNAMICS OF BONE TRAP-5B LEVEL IN PATIENTS WITH BONE METASTASES OF RENAL CELL CANCER AT COMBINED TREATMENT

  • Serhiy Boichuk National Cancer Institute
  • Anatoliy Diedkov National Cancer Institute
  • Viktor Kostiuk National Cancer Institute
  • Vasyliy Ostafiychuk National Cancer Institute
Keywords: tartrate-resistant acid phosphatase-5b, renal cell cancer (RCC), bone metastases, bisphosphonates, zolendronic acid, serum level

Abstract

The objective of this study was to determine the sensitivity of tartrate-resistant acid phosphatase (Bone TRAP-5b) for early detection of bone metastases (BM) and to investigate the efficacy of bisphosphonates (BF) (zolendronic acid-ZA) in prevention of bone metastases in patients with Renal Cell Carcinoma (RCC). The 60 patients with RCC with proven BM were investigated to assess the sensitivity and specificity of Bone TRAP-5b. 95 patients with RCC with high level of tartrate-resistant acid phosphatase (Bone TRAP-5b) (8,5±0,2 IU/L) after radical surgical treatment were divided into two groups: 1-st group: (n=44) received zolendronic acid (ZA) (BF +), and 2-nd group (n=51) patients didn’t receive ZA (BF-). Patients of both subgroups were similar by age, sex, stage of disease. The levels of Bone TRAP-5b, Ca++, alkaline phosphatase, LDG were accessed every 3 months, and MRI imaging, bone scan with 99mTc every 6 month in both groups. We determined the high correlation between bone TRAP-5b and the presence of bone metastases (r=0,9; p <0,05), but its level wasn’t dependent with the number of BM. The results showed the high sensitivity and specificity of Bone TRAP-5b at the critical value of 5.2 IU/L (98,3 % and 90,0 %), (χ2=64,6; p<0.01). Using BF for the prevention of bone metastases in high risk group patients with RCC provides a significant difference in the incidence of bone metastases in patients.

Downloads

Download data is not yet available.

Author Biographies

Serhiy Boichuk, National Cancer Institute

Department of Oncological Orthopedics, Skin Tumors And Soft Tissue Tumors

Anatoliy Diedkov, National Cancer Institute

Department of Oncological Orthopedics, Skin Tumors And Soft Tissue Tumors

Viktor Kostiuk, National Cancer Institute

Department of Oncological Orthopedics, Skin Tumors And Soft Tissue Tumors

Vasyliy Ostafiychuk, National Cancer Institute

Department of Oncological Orthopedics, Skin Tumors And Soft Tissue Tumors

References

Volkov, N. (2011). The Mechanism of bone metastases development. Practical oncology, 12 (3), 97–102.

Alekseev, B., Kaplinskiy, A. (2009). The new options for target therapy of the metastatic kidney cancer. Onkourology, 3, 8–12.

Semkov, A., Mahson, A., Peterson, S. et. al. (2010). The surgical treatment of bone metastases of kidney cancer. Oncourology, 4, 10–15.

Bolshakova, S. (2011). The skeletal metastases of breast cancer: a mechanism of development, complications, a modern view of the combination therapy with bisphosphonates and radiotherapy. The Bulletin of the Russian Scientific Center of Roentgenology, 3 (11). Available at: http://vestnik.rncrr.ru/vestnik/v11/papers/bolsh_v11.htm

Reinus, W. R., Khurana, J. S. et. al. (2010). Diagnostic Imaging of Musculoskeletal Diseases. A Systematic Approach. Philadelphia: Springer science+Business media, LLC, 302–308.

Snegovoy, A., Mandzyuk, L. (2011). The importance of biomarkers for determination of the treatment options and prognosis of malignant tumors. Practical Oncology, 2 (4), 166–170.

Lyubimova, N. V., Kushlinskiy, N. E. (2015). Biochemical markers of bone metastasis. Advances in Molecular Oncology, 2 (1), 61–75. doi: 10.17650/2313-805x.2015.2.1.61-75

Lyubimova, N. V., Kozharskaya, G. V., Portnoi, S. M., Kushlinskii, N. E. (2014). Biochemical Markers of Bone Metabolism in Breast Cancer. Bulletin of Experimental Biology and Medicine, 157 (6), 769–772. doi: 10.1007/s10517-014-2663-1

Preussner, R., Sauer-Eppel, H., Oremek, G. (2014). Tartrate-resistant acid phosphatase 5b as a diagnostic marker of bone metastases in patients with renal cell carcinoma. Integrative Cancer Science and Therapeutics, 1 (3), 35–38.

Chung, Y.-C., Ku, C.-H., Chao, T.-Y., Yu, J.-C., Chen, M. M., Lee, S.-H. (2006). Tartrate-Resistant Acid Phosphatase 5b Activity Is a Useful Bone Marker for Monitoring Bone Metastases in Breast Cancer Patients after Treatment. Cancer Epidemiology Biomarkers & Prevention, 15 (3), 424–428. doi: 10.1158/1055-9965.epi-04-0842

Wu, Y.-Y., Janckila, A. J., Ku, C.-H., Yu, C.-P., Yu, J.-C., Lee, S.-H. et. al. (2010). Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. BMC Cancer, 10 (1), 158. doi: 10.1186/1471-2407-10-158

Santoni, M., Conti, A., Procopio, G., Porta, C., Ibrahim, T., Barni, S. et. al. (2015). Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? Journal of Experimental & Clinical Cancer Research, 34 (1), 10. doi: 10.1186/s13046-015-0122-0

Ozu, C., Nakashima, J., Horiguchi, Y., Oya, M., Ohigashi, T., Murai, M. (2008). Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. International Journal of Urology, 15 (5), 419–422. doi: 10.1111/j.1442-2042.2008.02029.x

Smith, M. R., Cook, R. J., Coleman, R., Brown, J., Lipton, A., Major, P. et. al. (2007). Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer. Urology, 70 (2), 315–319. doi: 10.1016/j.urology.2007.03.071

Korpela, J., Tiitinen, S. L., Hiekkanen, H. et. al. (2006). Serum TRACP 5b and ICTP as a markers of bone metastases in breast cancer. Anticancer Research, 26, 3127–3132.

Yao, N.-S., Wu, Y.-Y., Janckila, A. J., Ku, C.-H., Hsieh, A.-T., Ho, C.-L. et. al. (2011). Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clinica Chimica Acta, 412 (1-2), 181–185. doi: 10.1016/j.cca.2010.09.038

Volosnev, L. V. (2013). The mechanismes of metastatic skeletal lesions and role of treatment with N-bosphosphonates. Oncology. P. A. Hertzen’ Journal, 1, 73–77.

Zaghloul, M. S., Boutrus, R., El-Hossieny, H., Kader, Y. A., El-Attar, I., Nazmy, M. (2010). A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. International Journal of Clinical Oncology, 15 (4), 382–389. doi: 10.1007/s10147-010-0074-5

Sahi, C., Knox, J. J., Clemons, M., Joshua, A. M., Broom, R. (2010). Renal cell carcinoma bone metastases: clinical advances. Therapeutic Advances in Medical Oncology, 2 (2), 75–83. doi: 10.1177/1758834009358417

Nenonen, A., Cheng, S., Ivaska, K. K., Alatalo, S. L., Lehtimaki, T., Schmidt-Gayk, H. et. al. (2005). Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover. Journal of Bone and Mineral Research, 20 (10), 1804–1812. doi: 10.1359/jbmr.050403


👁 272
⬇ 121
Published
2017-09-30
How to Cite
Boichuk, S., Diedkov, A., Kostiuk, V., & Ostafiychuk, V. (2017). DYNAMICS OF BONE TRAP-5B LEVEL IN PATIENTS WITH BONE METASTASES OF RENAL CELL CANCER AT COMBINED TREATMENT. EUREKA: Health Sciences, (5), 3-10. https://doi.org/10.21303/2504-5679.2017.00407
Section
Medicine and Dentistry